Mode
Text Size
Log in / Sign up

Alopecia Areata

Part of Androgenetic alopecia

12 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Alopecia Areata

34 trials tracked for Alopecia Areata: 10 in phase 3 or 4 and 7 with published results. The most-cited published study has 733 citations.

34Trials tracked
10Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 3 Phase 3 7 Phase 2 19 Phase 1 1 Other / NA 4
  1. Phase 4 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed · 733 cited
  2. Phase 3 A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Completed · 53 cited
  3. Phase 3 Long-Term PF-06651600 for the Treatment of Alopecia Areata Completed · 37 cited
  4. Phase 3 PF-06651600 for the Treatment of Alopecia Areata Completed · 29 cited
  5. Phase 3 A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Completed · 20 cited
  6. Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) Completed · 17 cited
Show 28 more trials
  1. Phase 4 Pain Outcomes Following Intralesional Corticosteroid Injections Completed · 9 cited
  2. Phase 4 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed
  3. Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) Completed
  4. Phase 3 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata Completed
  5. Phase 2 Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata Completed
  6. Phase 2 Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Completed
  7. Phase 2 Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata Completed
  8. Phase 2 Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Completed
  9. Phase 2 Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata Completed
  10. Phase 2 A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata Completed
  11. Phase 2 Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata Completed
  12. Phase 2 Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata Completed
  13. Phase 2 Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata Completed
  14. Phase 2 Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata Completed
  15. Phase 2 Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata Completed
  16. Phase 2 Tofacitinib for Immune Skin Conditions in Down Syndrome Completed
  17. Phase 2 An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata Completed
  18. Phase 2 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Completed
  19. Phase 2 Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Completed
  20. Phase 2 LEO 124249 Ointment in the Treatment of Alopecia Areata Completed
  21. Phase 2 Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata Completed
  22. Phase 2 Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed
  23. Phase 2 Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata Completed
  24. Phase 1 A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age Completed
  25. N/A Tofacitinib for the Treatment of Alopecia Areata and Its Variants Completed
  26. N/A Healthcare Disparities in Alopecia Areata Completed
  27. N/A Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata Completed
  28. N/A Alefacept in Patients With Severe Scalp Alopecia Areata Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Androgenetic alopecia

Related studies from across the Androgenetic alopecia family.

5-alpha-reductase inhibitors show no statistically significant association with suicide or neuropsychiatric events in BPH or AGA
Urology Meta-analysis
5-alpha-reductase inhibitors show no statistically significant association with suicide or neuropsychiatric events in BPH or AGA Trial shows 5-alpha-reductase inhibitors do not increase suicide risk
This meta-analysis of observational studies examined the risk of suicide and neuropsychiatric events in patients with benign prostatic hyper…
New data suggests that 5-alpha-reductase inhibitors for hair loss or prostate issues are not linked to higher rates of suicide or depression…
Inflammation and fibrosis coupling contribute to hair follicle miniaturization in androgenetic alopecia
Rheumatology Sys. Review
Inflammation and fibrosis coupling contribute to hair follicle miniaturization in androgenetic alopecia Inflammation and Fibrosis Linked to Hair Loss in Male Pattern Baldness
This mini-review explores the role of inflammation and fibrosis in androgenetic alopecia. The authors identify specific immune-enriched tran…
New research highlights how inflammation and tissue scarring may play a key role in why some people experience hair loss in androgenetic alo…
5-alpha-reductase inhibitors are associated with increased sexual adverse events in androgenetic alopecia patients
Oncology Meta-analysis
5-alpha-reductase inhibitors are associated with increased sexual adverse events in androgenetic alopecia patients Hair loss medications may cause some side effects for men
This systematic review of 41 studies evaluates the impact of finasteride and dutasteride on sexual dysfunction in patients with hair loss. T…
Men using finasteride or dutasteride for hair loss may experience sexual side effects, though most cases are mild and reversible when the dr…
Pilot Study Shows 2% Salicylic Acid Shampoo Reduces Scab Severity in Androgenetic Alopecia Patients
Rheumatology Cohort
Pilot Study Shows 2% Salicylic Acid Shampoo Reduces Scab Severity in Androgenetic Alopecia Patients Simple wash removes scabs after hair transplant surgery
This prospective, multicenter, single-arm pilot study evaluated 21 male patients using a 2% salicylic acid shampoo.
A new shampoo formula helps clear scabs after hair transplant surgery without causing pain or irritation for most patients.

Questions about Alopecia Areata

Is there evidence that upadacitinib helps treat concurrent Vitiligo and alopecia areata?

Yes, a case report shows upadacitinib 15 mg daily improved vitiligo repigmentation and alopecia areata hair regrowth in a patient with both conditions.

Full answer →
Is the topical treatment STS01 effective for patchy alopecia areata?

Yes, a phase 2 trial found that topical STS01 1% significantly improved hair regrowth in patchy alopecia areata compared to placebo.

Full answer →
Does having alopecia areata increase or decrease my risk of getting skin cancer?

Alopecia areata is linked to a lower risk of melanoma and possibly other skin cancers, not an increased risk.

Full answer →